Cookie Policy

We've put some small files called essential cookies on your device to help our site work on your browser.
We also use analytical cookies to help up improve our website by collecting and reporting information on it's usage.

You can read more above this on our Privacy Policy page.

I'm ok with analytical cookies Do not use analytics cookies

Investors Video and Audio

The content of all investor relations materials contained on this website are deemed to be correct at the time of issue/publication.


Shield Therapeutics ‘seeking to conclude US partnering discussions’

Jan 2020 - 9:18

Tim Watts, CFO, Shield Therapeutics (STX) provides an update outlining progress during 2019 which included the FDA approval of lead product, Feraccru®/Accrufer®.

Jan 2020 - 20:49

Shield Therapeutics ties up US$63million deal for Feraccru in China

Jan 2020 - 6:32

Shield Therapeutics discuss their Chinese licencing agreement plus John Meyer on Sirius and Arc Minerals

Jan 2020 - 23:30

Investival Showcase Presentations 2019 – Shield Therapeutics

Dec 2019 - 16:15

Dr Mark Sampson, CMO discusses Feraccru and data presented at UEG Week 2019

Oct 2019 - 6:18

Shield Therapeutics to present data showing Feraccru offers ‘real oral alternative’

Oct 2019 - 6:09

Tim Watts, CFO at Shield Therapeutics #STX presenting at our Life Sciences Investor Briefing

Sep 2019 - 28:21

Interim results for the six months ended 30 June 2019

Aug 2019 - 50:49

Shield Therapeutics ‘in a strong position’ and confident of a US Feraccru deal

Aug 2019 - 7:31

Elevator Pitches Reabold Resources, Block Energy and Shield Therapeutics

Aug 2019 - 36:00

Q&A with CEO of Shield Therapeutics (STX) Carl Sterritt

Aug 2019 - 9:04